Searching News Database: hereditary angioedema
HSMN NewsFeed - 14 Dec 2021
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
HSMN NewsFeed - 3 Jul 2020
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
HSMN NewsFeed - 23 Aug 2018
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
HSMN NewsFeed - 28 Aug 2017
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
HSMN NewsFeed - 21 Jul 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
HSMN NewsFeed - 3 Apr 2017
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
HSMN NewsFeed - 16 Jan 2017
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
HSMN NewsFeed - 29 Nov 2016
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 11 Nov 2016
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
HSMN NewsFeed - 12 Oct 2016
Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
HSMN NewsFeed - 29 Sep 2016
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
HSMN NewsFeed - 4 Apr 2016
Therabron Therapeutics Appoints Eric Richman as an Independent Board Member
Therabron Therapeutics Appoints Eric Richman as an Independent Board Member
HSMN NewsFeed - 16 Apr 2014
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
HSMN NewsFeed - 28 Feb 2013
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
HSMN NewsFeed - 30 Nov 2012
BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction
BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction
HSMN NewsFeed - 10 Apr 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
HSMN NewsFeed - 28 Nov 2011
CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy to Board of Directors
CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy to Board of Directors
HSMN NewsFeed - 27 Jan 2011
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
HSMN NewsFeed - 28 Dec 2010
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
HSMN NewsFeed - 13 Sep 2010
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
HSMN NewsFeed - 8 Jun 2009
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
HSMN NewsFeed - 13 Feb 2009
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
HSMN NewsFeed - 9 Feb 2009
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
HSMN NewsFeed - 4 Feb 2009
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
HSMN NewsFeed - 7 Aug 2008
Dyax Corp. Announces the Appointment of George Migausky as Chief Financial Officer
Dyax Corp. Announces the Appointment of George Migausky as Chief Financial Officer
HSMN NewsFeed - 15 Jul 2008
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
HSMN NewsFeed - 6 May 2008
Lev Pharmaceuticals Announces Cinryze(TM) Complete Response Submission Accepted for Review by FDA
Lev Pharmaceuticals Announces Cinryze(TM) Complete Response Submission Accepted for Review by FDA
HSMN NewsFeed - 24 Apr 2008
Jerini AG -- FDA Issues Not Approvable Letter for Icatibant in the Treatment of HAE
Jerini AG -- FDA Issues Not Approvable Letter for Icatibant in the Treatment of HAE
HSMN NewsFeed - 20 Mar 2008
Pharming to receive Negative Opinion on European Marketing Authorization Application for Rhucin(R)
Pharming to receive Negative Opinion on European Marketing Authorization Application for Rhucin(R)
HSMN NewsFeed - 26 Nov 2007
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
HSMN NewsFeed - 31 Oct 2007
Dyax Announces the Appointment of William Pullman as Executive Vice President and Chief Development Officer
Dyax Announces the Appointment of William Pullman as Executive Vice President and Chief Development Officer
HSMN NewsFeed - 10 Sep 2007
Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
HSMN NewsFeed - 30 Aug 2007
Pharming Presents Positive Results from European Phase III Trial of Rhucin(R)
Pharming Presents Positive Results from European Phase III Trial of Rhucin(R)
HSMN NewsFeed - 31 Jul 2007
Lev Pharmaceuticals Submits Biologics License Application for Cinryze(TM)
Lev Pharmaceuticals Submits Biologics License Application for Cinryze(TM)
HSMN NewsFeed - 26 Jun 2007
Lev Pharmaceuticals, Inc. Announces Completion of Marketing and Sales Management Team
Lev Pharmaceuticals, Inc. Announces Completion of Marketing and Sales Management Team
HSMN NewsFeed - 31 May 2007
Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
HSMN NewsFeed - 14 May 2007
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
HSMN NewsFeed - 4 May 2007
Dyax Announces the Resignation of Thomas Beck, M.D., President and Chief Operating Officer
Dyax Announces the Resignation of Thomas Beck, M.D., President and Chief Operating Officer
HSMN NewsFeed - 26 Apr 2007
Dyax Announces the Appointment of Gustav Christensen as Executive Vice President and Chief Business Officer
Dyax Announces the Appointment of Gustav Christensen as Executive Vice President and Chief Business Officer
HSMN NewsFeed - 17 Apr 2007
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
HSMN NewsFeed - 12 Apr 2007
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
HSMN NewsFeed - 1 Nov 2006
Pharming Shareholders Appoint Bruno Giannetti as Member of the Board of Management
Pharming Shareholders Appoint Bruno Giannetti as Member of the Board of Management
HSMN NewsFeed - 21 Jul 2006
Pharming Submits Marketing Authorisation Application for Recombinant Human C1 Inhibitor in Europe
Pharming Submits Marketing Authorisation Application for Recombinant Human C1 Inhibitor in Europe
HSMN NewsFeed - 24 May 2006
Dyax Announces the Appointment of Peggy Berry as Senior Vice President of Quality and Regulatory Affairs
Dyax Announces the Appointment of Peggy Berry as Senior Vice President of Quality and Regulatory Affairs
HSMN NewsFeed - 18 May 2006
Baxter and Jerini Advance Program to Develop Non-Intravenous Hemophilia Therapy
Baxter and Jerini Advance Program to Develop Non-Intravenous Hemophilia Therapy
Additional items found! 42
Members Archive contains
42 additional stories matching:
hereditary angioedema
(Password required)
hereditary angioedema
(Password required)